2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0320A
    Cromolyn disodium
    		Inhibitor 99.98%
    Cromolyn (Cromoglycate) disodium is an orally active GSK-3β inhibitor with an IC50 of 2.0 μM. Cromolyn disodium is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn disodium can be used in the research of bronchial asthma. In addition, Cromolyn disodium has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects.
    Cromolyn disodium
  • HY-P9967
    Aducanumab
    		Inhibitor 99.25%
    Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
    Aducanumab
  • HY-P1363B
    β-Amyloid (1-42), human, HFIP-treated
    		99.89%
    β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.
    β-Amyloid (1-42), human, HFIP-treated
  • HY-P99022
    Gantenerumab
    		Inhibitor 99.724%
    Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research.
    Gantenerumab
  • HY-17406
    Tolcapone
    		Inhibitor 99.86%
    Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma.
    Tolcapone
  • HY-P99859
    Donanemab
    		Inhibitor 99.19%
    Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.
    Donanemab
  • HY-N0009
    Geniposide
    		Antagonist 99.55%
    Geniposide is an iridoid glucoside extracted from Gardenia jasminoidesEllis fruits; exhibits a varity of biological activities such as anti-diabetic, antioxidative, antiproliferative and neuroprotective activities.
    Geniposide
  • HY-P1061A
    Colivelin TFA
    		99.52%
    Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury.
    Colivelin TFA
  • HY-N0615
    Notoginsenoside R1
    		Inhibitor 99.93%
    Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells.
    Notoginsenoside R1
  • HY-N2581
    Phytic acid sodium salt
    		Inhibitor
    Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) sodium salt is an orally active compound. Phytic acid sodium salt can be derived from the seeds of legumes. Phytic acid sodium salt is a [PO4]3- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid sodium salt attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid sodium salt can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.
    Phytic acid sodium salt
  • HY-101855
    Emrusolmin
    		Inhibitor 99.93%
    Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology.
    Emrusolmin
  • HY-N0022
    Isoacteoside
    		Inhibitor 99.73%
    Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities.
    Isoacteoside
  • HY-D0214
    Rose Bengal sodium
    		Inhibitor 99.49%
    Rose Bengal sodium, a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. It is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Rose Bengal sodium exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Rose Bengal sodium can inhibit Aβ aggregation through light irradiation. Rose Bengal sodium holds potential for use in cancer, viral infections, and neurodegenerative disease research.
    Rose Bengal sodium
  • HY-B0104
    Glimepiride
    		Inhibitor 99.92%
    Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.
    Glimepiride
  • HY-N0044
    Ginsenoside Re
    		Inhibitor 99.65%
    Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
    Ginsenoside Re
  • HY-P1362
    β-Amyloid (42-1), human
    		99.88%
    β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease.
    β-Amyloid (42-1), human
  • HY-10009
    Semagacestat
    		Inhibitor 98.61%
    Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease.
    Semagacestat
  • HY-N0373
    Licochalcone B
    		Inhibitor 99.91%
    Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction.
    Licochalcone B
  • HY-P2268
    RAGE antagonist peptide
    		Antagonist 98.81%
    RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities.
    RAGE antagonist peptide
  • HY-P0265A
    β-Amyloid (1-40) (human) TFA
    		99.89%
    β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease.
    β-Amyloid (1-40) (human) TFA
Cat. No. Product Name / Synonyms Application Reactivity